Pharmatalkradio

At the May 2015 Chief Medical Officer's Summit in Boston, we featured a session on: How Investors Assess R&D Biotech Management Take a look at the details below: In this session, we begin with a presentation on a perspective on the method of evaluating a disease space, which includes a comprehensive understanding of 1) the science, 2) the competitive landscape and 3) the management teams for each company. How does this get mapped out? Following will be more discussion on: Understanding the context of value proposition Strategic fit Processes used to evaluate management and an understanding of competitive strategy How best to convey your plans How best to communicate with investors (before investment) and boards (afterwards) – via the CEO or directly? Importance of clinical development plan expectations Moderated by: Peter Kolchinsky, PhD Managing Director, RA Capital Management, LLC Panelists: Jonathan Behr, PhD EIR and Market Sector Leader, Innovation, Partners Healthcare, David Berry, MD, PhD P